Shots:

• The P-II study involves assessing donanemab vs PBO in 272 patients with early symptomatic AD who were selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by PET imaging
• The study met its 1EPs- showed a slowing of decline by 32% @76wks. as measured by the iADRS. The secondary analyses showed consistent improvements in cognition & function decline on all 2EPs but did not reach nominal statistical significance on every 2EPs
• 40% of patients achieved amyloid negativity as early as 6mos. after starting treatment and 68% achieved the target by 18mos. Lilly plans to discuss the results with regulators to evaluate the next steps for donanemab

 ­ Ref: PRNewswire | Image: Eli Lilly